Citi Pharma Expands into Veterinary Healthcare with New Subsidiary

September 12, 2025 –

Citi Pharma Limited (CPHL) has formally launched its wholly owned subsidiary, Citi Veterinary Limited (CVL), marking its entry into Pakistan’s veterinary healthcare market. The new subsidiary has commenced operations with 32 veterinary products, including vaccines, and is targeting a turnover of Rs1.5 billion in FY25-26, with plans to scale up to Rs10 billion within three years.

According to the company’s notice to the Pakistan Stock Exchange (PSX), Letters of Credit (LCs) have already been established for eight products to ensure timely supply. CVL projects a 13% gross profit margin in its first operational year.

Backed by strong supply chain partnerships in China, CVL aims to ensure consistent product availability in the local market. The company has also submitted its layout plan to the Drug Regulatory Authority of Pakistan (DRAP), with inspection expected in December 2025. Trial production is scheduled for late FY25-26, while commercial production is planned for FY26-27.

In a strategic step, CVL is preparing to establish Pakistan’s first dedicated veterinary Active Pharmaceutical Ingredient (API) plant during FY26-27, which is expected to lift gross profit margins to around 25% through stronger value addition.

This expansion follows Citi Pharma’s earlier diversification moves, including the formation of Citi REIT Management Company, an antibiotic plant project, and discussions for a joint venture hospital with international partners.